Seek Returns

ALNY vs. PCVX: Alnylam Pharmaceuticals vs. Vaxcyte Stock Comparison

How do Alnylam Pharmaceuticals (ALNY) and Vaxcyte (PCVX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Alnylam Pharmaceuticals (ALNY) and Vaxcyte (PCVX) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Alnylam Pharmaceuticals (ALNY) has more than two decades of public-market history since June 1, 2004, whereas Vaxcyte (PCVX) listed on June 12, 2020 and has a much shorter record to draw on.

Company profile comparison for Alnylam Pharmaceuticals (ALNY) and Vaxcyte (PCVX)
Profile ItemALNYPCVX
NameAlnylam Pharmaceuticals, Inc.Vaxcyte Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization20.89 billion USD10.11 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJune 1, 2004June 12, 2020
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

ALNY
PCVX
GSPC
Loading price history…
Alnylam Pharmaceuticals (ALNY) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Alnylam Pharmaceuticals (ALNY) and Vaxcyte (PCVX). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Alnylam Pharmaceuticals (ALNY) and Vaxcyte (PCVX). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Alnylam Pharmaceuticals (ALNY) and Vaxcyte (PCVX)
MetricALNYPCVX
Total Return (1Y)-64.57%59.00%
Total Return (3Y, Annualized)-1.58%11.29%
Total Return (5Y, Annualized)-3.13%21.60%

Risk Profile

Drawdown History

ALNY
PCVX
GSPC
Loading price history…
Alnylam Pharmaceuticals (ALNY) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Alnylam Pharmaceuticals (ALNY) and Vaxcyte (PCVX). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Alnylam Pharmaceuticals (ALNY) and Vaxcyte (PCVX)
MetricALNYPCVX
Volatility (1Y, Annualized)54.08%56.01%
Beta (5Y)0.451.26
Max Drawdown (5Y)-68.25%-76.22%
Avg. Volume (3M)1.90M2.12M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ALNY and PCVX are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Alnylam Pharmaceuticals (ALNY) and Vaxcyte (PCVX)
MetricALNYPCVX
Sharpe Ratio (1Y)-1.270.98
Sortino Ratio (1Y)-1.451.76

Profitability

ROE (TTM)

Vaxcyte (PCVX) reports a negative ROE of -42.68%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Alnylam Pharmaceuticals (ALNY) reports 138.07%, ranking against industry peers normally.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

138.07%

ALNY
138.07%
Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-42.68%

Max
109.18%
Q3
6.23%
Median
-26.66%
PCVX
-42.68%
Q1
-64.05%
Min
-167.77%
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Vaxcyte (PCVX): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Alnylam Pharmaceuticals (ALNY) at 52.85% converts revenue to bottom-line profit above its industry’s benchmark range, while Vaxcyte (PCVX) at 0.00% keeps roughly the typical share for its industry.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

52.85%

ALNY
52.85%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
PCVX
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Vaxcyte (PCVX): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Alnylam Pharmaceuticals (ALNY) at 23.72% operates in the top operating margin quartile, ahead of Vaxcyte (PCVX) at 0.00%, which runs around its industry’s norm.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.72%

Max
83.12%
ALNY
23.72%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
83.12%
Q3
14.77%
PCVX
0.00%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Vaxcyte (PCVX): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Alnylam Pharmaceuticals (ALNY) and Vaxcyte (PCVX)
MetricALNYPCVX
ROE (TTM)138.07%-42.68%
ROA (TTM)9.51%-24.98%
Net Margin (TTM)52.85%0.00%
Operating Margin (TTM)23.72%0.00%
Gross Margin (TTM)77.28%0.00%

Growth

Revenue Growth

Only one side can be read here: Alnylam Pharmaceuticals (ALNY) reports revenue growth of 65.19%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.

Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Vaxcyte (PCVX): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Alnylam Pharmaceuticals (ALNY) nor Vaxcyte (PCVX) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for Alnylam Pharmaceuticals (ALNY) and Vaxcyte (PCVX)
MetricALNYPCVX
Revenue Growth (YoY)65.19%--
Revenue Growth (3Y CAGR)52.98%--
EPS Growth (YoY)----
EPS Growth (3Y CAGR)----

Financial Strength

Current Ratio (MRQ)

Both Alnylam Pharmaceuticals (ALNY) at 2.48 and Vaxcyte (PCVX) at 4.56 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.48

Max
25.13
Q3
12.13
Median
5.52
ALNY
2.48
Q1
2.47
Min
0.10

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.56

Max
25.13
Q3
12.13
Median
5.52
PCVX
4.56
Q1
2.47
Min
0.10
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Vaxcyte (PCVX): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Vaxcyte (PCVX) at 0.09 carries an industry-typical debt-to-equity mix, while Alnylam Pharmaceuticals (ALNY) at 0.83 uses more debt funding than most peers.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.83

Max
1.42
ALNY
0.83
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max
1.42
Q3
0.65
Median
0.15
PCVX
0.09
Q1
0.02
Min
0.00
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Vaxcyte (PCVX): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Alnylam Pharmaceuticals (ALNY) and Vaxcyte (PCVX)
MetricALNYPCVX
Current Ratio (MRQ)2.484.56
Debt / Equity (MRQ)0.830.09
Net Debt / EBITDA-0.57--

Dividends

Dividend Yield (TTM)

Neither Alnylam Pharmaceuticals (ALNY) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ALNY
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Vaxcyte (PCVX): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Alnylam Pharmaceuticals (ALNY) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ALNY
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Vaxcyte (PCVX): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Alnylam Pharmaceuticals (ALNY) and Vaxcyte (PCVX)
MetricALNYPCVX
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Alnylam Pharmaceuticals (ALNY) trades at 7.88 times trailing earnings, ranked against its peers, while Vaxcyte (PCVX) has no P/E ratio this period.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.88

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
ALNY
7.88
Min
0.07

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
PCVX
--
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Vaxcyte (PCVX): PCVX does not report P/E ratio, so it has no value marker; ALNY is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

A sales-based read is only available for Alnylam Pharmaceuticals (ALNY), whose P/S ratio of 4.17 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.17

Max
58.18
Q3
25.77
Median
7.30
ALNY
4.17
Q1
3.01
Min
0.01

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
PCVX
--
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Vaxcyte (PCVX): PCVX does not report P/S ratio, so it has no value marker; ALNY is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

On P/B ratio, both Alnylam Pharmaceuticals (ALNY) at 5.79 and Vaxcyte (PCVX) at 3.83 are valued close to their industries’ norm against book — neither stands out from peers.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.79

Max
13.53
Q3
6.54
ALNY
5.79
Median
3.25
Q1
1.69
Min
-5.59

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.83

Max
13.53
Q3
6.54
PCVX
3.83
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Alnylam Pharmaceuticals (ALNY) vs. Vaxcyte (PCVX): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Alnylam Pharmaceuticals (ALNY) and Vaxcyte (PCVX)
MetricALNYPCVX
P/E Ratio (TTM)7.88--
P/S Ratio (TTM)4.17--
P/B Ratio (MRQ)5.793.83
Free Cash Flow Yield (TTM)1.57%-5.24%